The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

• Principais autores: Xingli Zhou (Autor), Tongying Zhan (Autor), Xiaoxi Xu (Autor), Tianjiao Lan (Autor), Hongxiang Hu (Autor), Yuxi Zhou (Autor), Dengmei Xia (Autor), Jinqiu Wang (Autor), Yiyi Wang (Autor), Yue Xiao (Autor), Wei Li (Autor)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

AbstractBackground Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on the optimum dosage has been achieved.Objectives To investigate the efficacy and safety of low-dose RTX (a single inf...